<?xml version="1.0" encoding="UTF-8"?>
<project>
  <language>en</language>
  <availableLanguages readOnly="true">en</availableLanguages>
  <rcn>264008</rcn>
  <id>101164403</id>
  <acronym>pHyph</acronym>
  <teaser><![CDATA["There is a large unmet medical need for an efficient and highly accessible solution that can simultaneously treat and prevent BV and VVC, while removing the abuse of antibiotic and antimycotic drugs to avoid further antimicrobial resistance. The inefficacy of current...]]></teaser>
  <objective><![CDATA["There is a large unmet medical need for an efficient and highly accessible solution that can simultaneously treat and prevent BV and VVC, while removing the abuse of antibiotic and antimycotic drugs to avoid further antimicrobial resistance. The inefficacy of current solutions is demonstrated by the huge burden that BV/VCC bring to the society in terms of economic expenses (more than 3.8Bn annually), preterm births (5.4M per year), the huge prevalence of both diseases (more than 500M cases per year) and the deteriorated QoL for women. Gedea has developed pHyph, a patented pessary that due to its safe profile will be highly accessible as a first line OTC solution. pHyph is an antimicrobial-free dual solution with a new mode of action that targets both the treatment and prevention of BV and VVC, without the need of pathogen identification. pHyph will be commercialized as an OTC product in pharmacies and drug stores  where 90% of women with VI look for a treatment to the infection. The business model targeted for pHyph is a well-established and successful B2B2C model for this type of product. Our business model is highly scalable via planned partnerships with distributors and pharma companies, that will facilitate accelerated commercial deployment & scale up of our business throughout Europe & beyond.  Gedea core team is composed by 9 persons with over 250 years of experience combined, including experts in clinical research, bioorganic chemistry, regulatory affairs, marketing, and business development. The company received the award ""Rapidus Company of the Year"" and appeared on Labiotech's list ""The 20 European Biotech Companies to Watch in 2022"".
During this project, Gedea will perform the necessary clinical trials, CE-Mark Certification and pre-market activities to commercialize pHyph (TRL 9 by 2026). In order to do so, Gedea requires an estimated expenditure of 11.9M, which is requested to the EIC through both Grant and Equity fund."]]></objective>
  <title>Breakthrough dual-action OTC tablet for treatment and prevention of both bacterial and fungal vaginitis</title>
  <keywords>bacterial vaginosis, vaginal infections, vaginitis, vulvovaginal candidiasis, antimicrobial resistance, vaginal pessary, Lactobacillus, vaginal pH modulation</keywords>
  <totalCost>3799375</totalCost>
  <ecMaxContribution>2499999</ecMaxContribution>
  <startDate>2024-04-01</startDate>
  <endDate>2026-07-31</endDate>
  <ecSignatureDate>2024-06-07</ecSignatureDate>
  <duration>28</duration>
  <status>SIGNED</status>
  <identifiers>
    <grantDoi>10.3030/101164403</grantDoi>
  </identifiers>
  <validation>
    <euroSciVoc>false</euroSciVoc>
  </validation>
  <sourceUpdateDate>2024-12-31 09:30:22</sourceUpdateDate>
  <contentCreationDate readOnly="true">2024-06-10 15:57:58</contentCreationDate>
  <contentUpdateDate>2024-06-10 15:57:43</contentUpdateDate>
  <lastUpdateDate readOnly="true">2025-11-11 10:31:07</lastUpdateDate>
  <relations>
    <associations>
      <article source="editorial" type="relatedArticle">
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <rcn>452179</rcn>
        <id>452179-non-prescription-non-antibiotic-tablet-treats-bacterial-and-fungal-vaginitis</id>
        <title>Non-prescription, non-antibiotic tablet treats bacterial and fungal vaginitis</title>
        <contentUpdateDate>2024-10-10 13:55:44</contentUpdateDate>
        <relations>
          <categories>
            <category classification="applicationDomain" type="isApplicableIn">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/health</code>
              <title>Health</title>
              <displayCode readOnly="true">/Health</displayCode>
            </category>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/projectDescription</code>
              <title>Project description</title>
              <description>Article: description of linked project written by editorial team</description>
              <displayCode readOnly="true">/Project description</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/editorial</code>
              <title>CORDIS Editorial</title>
              <description>Written by CORDIS</description>
              <displayCode readOnly="true">/CORDIS Editorial</displayCode>
            </category>
          </categories>
        </relations>
      </article>
      <call source="corda" type="relatedMasterCall">
        <rcn>55873</rcn>
        <title>HORIZON-EIC-2023-ACCELERATOR-01</title>
        <identifier>HORIZON-EIC-2023-ACCELERATOR-01</identifier>
      </call>
      <call source="corda" type="relatedSubCall">
        <rcn>55873</rcn>
        <title>HORIZON-EIC-2023-ACCELERATOR-01</title>
        <identifier>HORIZON-EIC-2023-ACCELERATOR-01</identifier>
      </call>
      <organization source="corda" order="1" ecContribution="2499999" terminated="false" sme="true" netEcContribution="2499999" totalCost="3799375" type="coordinator">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>1954249</rcn>
        <id>911525006</id>
        <vatNumber>SE559000702601</vatNumber>
        <legalName>GEDEA BIOTECH AB</legalName>
        <address>
          <street>MEDICON VILLAGE SCHEELEVAGEN 2</street>
          <city>Lund</city>
          <postalCode>223 81</postalCode>
          <country>SE</country>
          <geolocation>55.7115222,13.2179207</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/PRC</code>
              <title>Private for-profit entities (excluding Higher or Secondary Education Establishments)</title>
              <displayCode readOnly="true">/Private for-profit entities (excluding Higher or Secondary Education Establishments)</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <name>Skåne län</name>
              <rcn>473440388</rcn>
              <nutsCode>SE224</nutsCode>
              <parents>
                <region>
                  <name>Sydsverige</name>
                  <rcn>473440424</rcn>
                  <nutsCode>SE22</nutsCode>
                  <parents>
                    <region>
                      <name>Södra Sverige</name>
                      <rcn>473442856</rcn>
                      <nutsCode>SE2</nutsCode>
                      <parents>
                        <region>
                          <name>Sweden</name>
                          <rcn>473598504</rcn>
                          <nutsCode>SE</nutsCode>
                          <euCode>SE</euCode>
                          <isoCode>SE</isoCode>
                        </region>
                      </parents>
                    </region>
                  </parents>
                </region>
              </parents>
            </region>
            <region type="relatedRegion">
              <name>Sweden</name>
              <rcn>473598504</rcn>
              <nutsCode>SE</nutsCode>
              <euCode>SE</euCode>
              <isoCode>SE</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <programme source="corda" uniqueProgrammePart="true" type="relatedLegalBasis">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>705792</rcn>
        <id>HORIZON.3.1</id>
        <code>HORIZON.3.1</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.3.1</pga>
        <title>The European Innovation Council (EIC)</title>
        <parent>
          <programme>
            <rcn>705791</rcn>
            <code>HORIZON.3</code>
            <parent>
              <programme>
                <rcn>705725</rcn>
                <code>HORIZON</code>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode readOnly="true">/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme source="corda" type="relatedTopic">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>707276</rcn>
        <id>HORIZON_HORIZON-EIC-2023-ACCELERATOROPEN-01</id>
        <code>HORIZON-EIC-2023-ACCELERATOROPEN-01</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <title>EIC Accelerator Open 2023</title>
        <parent>
          <programme>
            <rcn>20300</rcn>
            <code>HORIZON-Topics</code>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/topic</code>
              <title>Topic</title>
              <description>Programme: Part of the Commission work programme implementing legal basis</description>
              <displayCode readOnly="true">/Topic</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <result source="corda" type="relatedResult">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>1355490</rcn>
        <id>101164403_PSHORIZON</id>
        <title>Periodic Reporting for period 1 - pHyph (Breakthrough dual-action OTC tablet for treatment and prevention of both bacterial and fungal vaginitis)</title>
        <teaser>Bacterial Vaginosis (BV) and Vulvovaginal Candidiasis (VVC) are two of the most common vaginal infections affecting women globally, with over 500 million cases each year. These infections not only cause significant discomfort and reduce quality of life, but also contribute to...</teaser>
        <description>periodic</description>
        <sourceUpdateDate>2025-10-28 03:27:07</sourceUpdateDate>
        <contentUpdateDate>2025-11-11 10:31:02</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/pubsum</code>
              <title>Report Summary</title>
              <description>Result: Publishable summary (FP7 SESAM) and Summary for publication (H2020 SyGMa)</description>
              <displayCode readOnly="true">/Report Summary</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
          <associations>
            <webItem source="corda" type="relatedResultAttachment">
              <language>en</language>
              <availableLanguages readOnly="true">en,any</availableLanguages>
              <uri>/docs/results/horizon/101164/101164403_PS/picture1.jpg</uri>
              <alternativeText>pHyph package that we have suggested for CE-marking, in compliance with the MDR requirements.</alternativeText>
              <mimetype readOnly="true">image/jpeg</mimetype>
              <size readOnly="true">46080</size>
            </webItem>
            <webItem source="corda" type="relatedResultAttachment">
              <language>en</language>
              <availableLanguages readOnly="true">en,any</availableLanguages>
              <uri>/docs/results/horizon/101164/101164403_PS/picture3.jpg</uri>
              <alternativeText>pHyph tablets from the test batch at Acino</alternativeText>
              <mimetype readOnly="true">image/jpeg</mimetype>
              <size readOnly="true">28672</size>
            </webItem>
            <webItem source="corda" type="relatedResultAttachment">
              <language>en</language>
              <availableLanguages readOnly="true">en,any</availableLanguages>
              <uri>/docs/results/horizon/101164/101164403_PS/picture4.jpg</uri>
              <alternativeText>pHyph tablets from the test batch at Acino</alternativeText>
              <mimetype readOnly="true">image/jpeg</mimetype>
              <size readOnly="true">21504</size>
            </webItem>
            <webItem source="corda" type="relatedResultAttachment">
              <language>en</language>
              <availableLanguages readOnly="true">en,any</availableLanguages>
              <uri>/docs/results/horizon/101164/101164403_PS/picture2.jpg</uri>
              <alternativeText><![CDATA[Annette Säfholm, CEO & Eva Norell, Marketing & Comms Manager, receiving Arvind Hund Scale Up Award]]></alternativeText>
              <mimetype readOnly="true">image/jpeg</mimetype>
              <size readOnly="true">45056</size>
            </webItem>
          </associations>
        </relations>
      </result>
    </associations>
    <categories>
      <category classification="collection" type="belongsTo">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/project</code>
        <title>Project</title>
        <description>Project factsheets</description>
        <displayCode readOnly="true">/Project</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/21/35/159</code>
        <title>pharmacology and pharmacy</title>
        <displayCode readOnly="true">/medical and health sciences/basic medicine/pharmacology and pharmacy</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/digitalAgenda</code>
        <title>Digital agenda</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development of digital technologies and the digitisation of the economy and society (known as ‘Digital transition’).</description>
        <displayCode readOnly="true">/Digital agenda</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/cleanAir</code>
        <title>Clean air</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to the clean air policy (National Emission Ceiling Directive) aiming to improve ambient air quality and tackle air pollution, to protect the environment and human health.</description>
        <displayCode readOnly="true">/Clean air</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/ai</code>
        <title>Artificial intelligence</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development and deployment of AI-based technologies and solutions. Projects that develop AI-tools as part of their research method are included</description>
        <displayCode readOnly="true">/Artificial intelligence</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/climate</code>
        <title>Climate action</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to both mitigating climate change (e.g., contributions to the reduction of greenhouse gas emissions) and adapting to climate change by building resilience (e.g., regarding floods, droughts, spatial planning and better governance, adaptation to changing climate in value chains, etc.).</description>
        <displayCode readOnly="true">/Climate action</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/biodiversity</code>
        <title>Biodiversity</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to Europe’s biodiversity’s path to recovery including species protection, ecosystem conservation, and habitat rehabilitation, all essential for resilience in climate adaptation and addressing ecosystem services but also environmental crime and the health-environment connection.</description>
        <displayCode readOnly="true">/Biodiversity</displayCode>
      </category>
      <category classification="projectFundingSchemeCategory" type="relatedProjectFundingSchemeCategory">
        <language>en</language>
        <availableLanguages readOnly="true">en</availableLanguages>
        <code>/HORIZON-EIC-ACC-BF</code>
        <title>HORIZON EIC Accelerator Blended Finance</title>
        <description>HORIZON EIC Accelerator Blended Finance</description>
        <displayCode readOnly="true">/HORIZON EIC Accelerator Blended Finance</displayCode>
      </category>
      <category classification="source" type="isProvidedBy">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/corda</code>
        <title>CORDA</title>
        <description>RTD research data warehouse</description>
        <displayCode readOnly="true">/CORDA</displayCode>
      </category>
    </categories>
  </relations>
</project>
